Skin Cancer

This retrospective cohort study demonstrates the heightened risks individuals with actinic keratoses have for developing skin cancers.

BRAF mutations were addressed in depth this year, having been mentioned in 3 of this year’s top 5 articles. Also discussed were a first-in-its-class combination treatment approval and potential indicators of increased skin cancer risk.

In this study, researchers treated 37 basal cell carcinoma (BCC) lesions from 30 patients, with follow-ups at 5 time points after baseline examination.

Moderna’s mRNA-4157/V940 combined with Merck’s pembrolizumab reduced melanoma recurrence and death; HHS proposed permanently implementing emergency opioid use disorder policies enacted in 2020; maternal death rates were 62% higher in 2020 in states that now have abortion restrictions.

Response, progression-free survival, overall survival, time-to-next-treatment, and toxicity outcomes were evaluated among patients with advanced cutaneous squamous cell carcinoma (cSCC) who received first-line treatment with immune checkpoint inhibitors.

From comparing outcomes, it is known that cemiplimab has the potential to improve responses among patients who have cutaneous squamous cell carcinoma (cSCC), although many important questions remain, explained Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center

Malignant cutaneous melanoma outcomes were investigated as they relate to diagnosis delay and potential influence from socioeconomic and demographic factors in Brazil, where skin cancer diagnoses represent 30% of all cancer diagnoses.

The study's goal was to clarify possible second and third skin cancer development patterns among organ transplant recipients who developed more than 1 instance of skin cancer and to better characterize this patient population by patient age and transplanted organ type.

While immunocryosurgery is known to be effective against primary nonsuperficial basal cell carcinoma (BCC), there is less data on its effectiveness in relapsed BCC.

Currently, there is no treatment approved for resectable cutaneous squamous cell carcinoma (cSCC), nor do we have biomarkers to predict treatment response, noted Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center

The increasing rate of melanoma diagnosis may not be due to actual disease, the authors of a new study posit; instead, it may be due to overdiagnosis of patients with an actual very low risk of death.

Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center, discusses the results of study he and his team conducted in the setting of resectable stage II to IV cutaneous squamous cell carcinoma.

This investigation compared the histologic features of basal cell carcinoma (BCC) between organ transplant recipients and the general population.

The risks of 4 types of skin cancers were investigated among patients who have neurofibromatosis type 1, a multisystem autosomal dominant genetic syndrome characterized by loss of neurofibromin.

Patients may be able to forgo radiation following use of cemiplimab to treat their resectable cutaneous squamous cell carcinoma (cSCC), as it is likely to demonstrate significant improvement in quality of life (QOL) for patients and enable less invasive surgeries, noted Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center.

Dermoscopy is a relatively inexpensive and readily available tool that can improve outcomes and quality of life for patients who need surgical excision of nonmelanoma skin cancers, the authors found.

Electrochemotherapy in basal cell carcinoma (BCC) was evaluated for its utilization practicality, efficacy, and safety, as well as factors that may predict disease response to the treatment.

Neil D. Gross, MD, FACS, is head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at MD Anderson.

This new study explored the diagnostic utility and accuracy of 2-photon fluorescence microscopy (TPFM) among nonmelanoma skin cancers, which included basal cell carcinoma and squamous cell carcinoma.

This new study investigated risk factors for basal cell carcinoma (BCC) recurrence in the head and neck region.

Despite some differences in the frequency of dermoscopic features between basal cell carcinoma (BCC) and benign skin tumors, dermoscopy alone is not sufficient for a reliable diagnosis, according to a recent study.

Previous study results on incidence of skin cancers in persons with albino skin who live in Africa have been inconsistent, despite this population having a known higher risk for the disease.

In this interview with The American Journal of Managed Care® (AJMC®), Igor Puzanov, MD, of Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, discusses the state of treatment selection in the setting of resected advanced melanoma, why sequencing of therapies does not occur in the setting of adjuvant therapy, and best practices to keep in mind for patient education and managing their treatment-related toxicities.

Quantifying the risk of malignant melanoma from methotrexate use proved difficult in this new study, with the authors calling for larger studies with longer follow-up to guide future practice in the space.

In this new study, investigators searched for potential predictors of melanoma thickness, with implications for treatment decisions regarding biopsy and excision margins.